How should I initiate tumor necrosis factor (TNF) inhibitor therapy, including choice of agent, dosing, tuberculosis screening, contraindications, and monitoring?

TNF Inhibitor Initiation Protocol

Before starting any TNF inhibitor, you must screen for tuberculosis using both tuberculin skin test (TST) and interferon-gamma release assay (IGRA), treat latent TB infection if detected, and wait at least 1 month after starting LTBI treatment before initiating the TNF inhibitor.

Tuberculosis Screening (Mandatory)

Screening Tests Required

• Perform both TST and IGRA in combination for maximum sensitivity 1, 2
  • TST alone misses cases due to immunosuppression from underlying disease and medications (prednisolone and azathioprine reduce TST sensitivity) 3
  • IGRA-alone strategies reduce LTBI treatment rates but may miss cases 4
  • Combined testing increases detection sensitivity, which is critical given the high TB risk with TNF inhibitors

Additional TB Screening Components

• Chest X-ray (mandatory for all patients) 5
  • Gohn complex present → treat for LTBI
  • Healed lesions → exclude active TB first
  • Suspected active lesions → confirm/exclude active TB before any treatment
• Clinical assessment: history of TB exposure, prior TB infection, endemic area residence 5
• Physical exam: lung/heart auscultation, lymph node examination 5

TB Risk by Agent

The risk varies significantly between TNF inhibitors 1:

• Highest risk: Adalimumab (relative risk 29.3) and Infliximab (relative risk 18.6)
• Lower risk: Newer TNF inhibitors (etanercept, certolizumab, golimumab)

LTBI Treatment Protocol

When to Treat

• Positive TST (≥5mm induration; if <5mm, repeat in 1-2 weeks on opposite arm) 6
• Positive IGRA result
• Radiographic evidence of old TB (Gohn complex) 5
• Consider treatment even with negative tests in immunosuppressed patients with high TB risk 6

LTBI Treatment Regimens

• Isoniazid for 9 months (traditional regimen)
• Rifampicin for 4 months (shorter, improves completion rates) 2
• Isoniazid/rifampicin for 3 months (shorter alternative) 2

Timing of TNF Inhibitor Initiation

• LTBI treatment: Start TNF inhibitor 1 month after beginning LTBI therapy 6
• Active TB treatment: Start TNF inhibitor 2 months after beginning active TB therapy 6
• Exception: If disease activity is severe and requires immediate treatment, these timelines can be followed rather than waiting for completion 6

Other Pre-Treatment Screening

Infectious Disease Screening

• Hepatitis B: HBsAg, anti-HBc, anti-HBs testing 5
  • HBsAg-positive patients require antiviral prophylaxis at TNF inhibitor start
• HIV testing 5
• Varicella zoster virus: antibody test if prior infection uncertain 5

Vaccinations (Complete Before Starting)

• Pneumococcal vaccine (23-valent) - recommended 5
• Hepatitis B vaccine - consider in seronegative patients 5
• Annual influenza vaccine - recommended 5
• VZV vaccine - consider if no prior infection 5

Contraindications to Screen For

• Absolute contraindications 7:
  • Active tuberculosis (until treated appropriately)
  • Active serious infections
  • Congestive heart failure (NYHA class III-IV)
  • Demyelinating disease
  • Recent malignancy (<5 years requires careful consideration) 5

Choice of Agent

First-Line TNF Inhibitors

For most indications, TNF inhibitors are preferred over other biologics (IL-17 inhibitors, JAK inhibitors) due to greater experience and established long-term safety 7

Special Considerations

• Inflammatory bowel disease: Avoid IL-17 inhibitors (secukinumab, ixekizumab) as they are ineffective or worsen IBD 7
• Contraindication to TNF inhibitors due to infection risk: Consider sulfasalazine over other biologics 7
• Heart failure or demyelinating disease: Use IL-17 inhibitors (secukinumab/ixekizumab) instead 7

Monitoring After Initiation

Therapeutic Drug Monitoring

For inflammatory bowel disease patients on TNF inhibitors 8:

• Target trough levels:
  • Infliximab: 6.1-10.0 mg/L (IV formulation)
  • Adalimumab: 10.1-12.0 mg/L
  • Subcutaneous infliximab: >13 μg/mL (concentrations >20 μg/mL associated with deep remission)
• Timing: Measure at week 14 after initiation to predict long-term remission 8
• Note: SC formulations maintain more consistent levels than IV; IV and SC infliximab levels are not equivalent 8

Ongoing TB Surveillance

• Repeat TB screening only in patients at increased ongoing risk of TB exposure 2
• Monitor for TB symptoms: fever, weight loss, cough, night sweats 9
• High suspicion for atypical presentations: TB during TNF inhibitor therapy presents more commonly as extrapulmonary or disseminated disease 1, 10

Critical Pitfalls to Avoid

1. Do not rely on TST alone in immunosuppressed patients - sensitivity is reduced 3
2. Do not use IGRA-alone in high-risk populations - combination testing is safer 2
3. Do not delay LTBI treatment - must start before TNF inhibitor 11
4. Do not miss extrapulmonary TB - maintain high clinical suspicion as sputum smear-negative and extrapulmonary TB are more common in TNF inhibitor users 10
5. Do not abruptly stop TNF inhibitor if TB develops - this increases immune reconstitution inflammatory syndrome risk 1